Expressive

rs12127679 (LINC02774): HCTZ Metabolic Response

Key takeaways

  • rs12127679 sits within LINC02774, a non-coding RNA gene that does not produce a protein.
  • This variant was examined in a genome-wide study of metabolic side effects from hydrochlorothiazide (HCTZ), a diuretic prescribed for high blood pressure.
  • The study focused on African American participants from two pharmacogenetic clinical trials (PEAR and GERA).
  • The primary genome-wide significant findings in the study were at the NELL1 gene, not the LINC02774 locus.
  • Evidence for rs12127679 specifically is preliminary, with no replicated associations currently on file.

Key takeaways

  • rs12127679 sits within LINC02774, a long intergenic non-coding RNA (lincRNA) locus - meaning this region produces RNA but does not encode a protein.
  • This variant was examined in a genome-wide association study (GWAS) of adverse metabolic responses to hydrochlorothiazide (HCTZ), one of the most prescribed blood pressure medications in the United States, accounting for over 110 million annual prescriptions.
  • The study focused on African American participants with mild-to-moderate primary hypertension enrolled across two pharmacogenetic clinical trials.
  • The study's genome-wide significant signals were at the NELL1 gene (11p15.1), not at the LINC02774 locus; evidence for rs12127679 specifically is preliminary.
  • No replicated associations or lifestyle considerations are currently on file for this variant.

What the research says A GWAS and meta-analysis examined changes in fasting plasma glucose and blood triglycerides in response to HCTZ treatment, drawing participants from two pharmacogenetic clinical trials - the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and the Genetic Epidemiology of Responses to Antihypertensive (GERA) studies. The genome-wide scan covered African American participants with mild-to-moderate primary hypertension who were randomized to HCTZ at 12.5-25 mg daily (more than 90% of PEAR participants received the higher 25 mg dose). The study's headline findings pointed to two variants in NELL1 (rs12279250 and rs4319515, r²=0.73 at 11p15.1), each associated with a ~28 mg/dL increase in triglyceride change per variant allele; rs12127679 in the LINC02774 region was among the variants assessed in the genome-wide sweep, but the available study text does not report a genome-wide significant or specifically quantified association for this locus.

Reported associations

  • HCTZ-induced triglyceride change: The GWAS examined triglyceride response to HCTZ in African Americans; the study's primary genome-wide significant hits were at NELL1 (rs12279250 and rs4319515, each associated with ~28 mg/dL greater triglyceride increase per variant allele), not at this locus. No specific effect size for rs12127679 is reported in the available study materials.
  • HCTZ-induced fasting glucose change: The GWAS also examined changes in fasting plasma glucose following HCTZ treatment; specific results for rs12127679 are not detailed in the available study excerpt.

Evidence quality The underlying GWAS pooled participants from two clinical trials (PEAR and GERA), both enrolling individuals with mild-to-moderate primary hypertension, with no prior history of heart disease or diabetes mellitus. The study identified genome-wide significant associations for two NELL1 variants for triglyceride changes in African Americans, but no specific p-value, odds ratio, or effect size is reported in the available text for rs12127679 at the LINC02774 locus. Evidence for this variant remains preliminary: no replicated association, no quantified effect size, and no independent cohort validation is reported in the provided materials. The biological function of LINC02774 as a long intergenic non-coding RNA is not characterized by this study.

Lifestyle considerations No lifestyle considerations on file for this variant.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Bloodwork

  • metabolic panel if on thiazide therapy Moderate

    rs12127679-T carriers show increased metabolic dysfunction risk with thiazide use

    baseline and every 3-6 months: fasting glucose, lipid panel, electrolytes

Discuss with your doctor

  • thiazide sensitivity and alternative agents Moderate

    rs12127679-T allele carriers experience adverse metabolic effects from thiazide diuretics

    discuss metabolic risk with prescriber if considering thiazide for hypertension treatment

Frequently asked questions

What is rs12127679?

rs12127679 is a DNA variant (single-nucleotide polymorphism) located in LINC02774, a long intergenic non-coding RNA gene. It was studied as part of a genome-wide scan examining genetic influences on metabolic side effects from the blood pressure drug hydrochlorothiazide (HCTZ).

What is LINC02774?

LINC02774 is a long intergenic non-coding RNA (lincRNA) gene, meaning the DNA in this region is transcribed into RNA but does not encode a protein. Its precise biological function is not established by current available research.

Is rs12127679 linked to blood pressure medication side effects?

This variant was identified in a genome-wide study of metabolic side effects from hydrochlorothiazide (HCTZ) in African Americans, including changes in blood triglycerides and fasting glucose. However, the study's genome-wide significant findings centered on a different gene (NELL1), and no specific confirmed association has been reported for rs12127679 in available materials.

What is hydrochlorothiazide (HCTZ)?

Hydrochlorothiazide (HCTZ) is a thiazide diuretic - a water pill commonly prescribed for high blood pressure, with over 110 million prescriptions annually in the United States. Known side effects include increases in blood glucose and triglyceride levels, though the underlying mechanisms are not fully understood.

How reliable is the current evidence for rs12127679?

Evidence is preliminary and limited. The variant was examined in a single GWAS of HCTZ side effects; the study's headline findings were at a different locus (NELL1, with ~28 mg/dL triglyceride change per variant allele). No specific effect size, replication study, or confirmed association has been reported for rs12127679 in available materials.